Joseph Rubinfeld
Plus aucun poste en cours
Historique de carrière de Joseph Rubinfeld
Anciens postes connus de Joseph Rubinfeld
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| LADRX CORPORATION | Directeur/Membre du Conseil | 01/07/2002 | 26/12/2016 |
| Independent Dir/Board Member | 01/07/2002 | 26/12/2016 | |
| REGENICIN, INC. | Directeur/Membre du Conseil | 25/08/2010 | 26/12/2016 |
| Independent Dir/Board Member | 24/08/2010 | 12/05/2014 | |
| AMARANTUS BIOSCIENCE HOLDINGS, INC. | Directeur/Membre du Conseil | 05/12/2014 | 26/12/2016 |
| Independent Dir/Board Member | 05/12/2014 | 26/12/2016 | |
SuperGen, Inc.
 SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Directeur/Membre du Conseil | 08/02/2005 | 08/02/2005 |
| Directeur Technique/Scientifique/R&D | 08/02/2005 | 08/02/2005 | |
| Fondateur | 08/02/2005 | 08/02/2005 | |
| AMGEN INC. | Directeur des opérations | 01/01/1983 | 01/01/1983 |
| Fondateur | 01/01/1983 | 01/01/1983 | |
| Cetus Corp. | Directeur/Membre du Conseil | 01/01/1968 | 01/01/1980 |
Vivacitas Oncology, Inc.
 Vivacitas Oncology, Inc. Medical/Nursing ServicesHealth Services Vivacitas Oncology, Inc. is a private clinical stage biopharmaceutical company founded in 2015 by Dr. Joseph Rubinfeld and Infusion 51a, LP. The company is based in Walnut Creek, CA. Vivacitas Oncology is focused on combating cancers that have proven to be resistant to current treatment modalities. The company aims to improve upon well-known chemotherapies with demonstrated effect, but which also possess challenges with potency, toxicity, stability, and other issues limiting their use. The CEO is Mark J. Suseck. | Fondateur | 01/01/2015 | - |
Imcure Therapeutics, Inc.
 Imcure Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Imcure Therapeutics, Inc. provides biopharmaceutical products. The firm develops small molecule therapeutics to treat diseases. The company was founded by Joseph Rubinfeld in December 2003 and is headquartered in San Francisco, CA. | Fondateur | - | - |
| SAREPTA THERAPEUTICS, INC. | Directeur/Membre du Conseil | - | - |
| ░░░░░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░░░░░░░░░░░ ░░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - | - |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Formation de Joseph Rubinfeld
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
| The City College of New York | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 15 |
Opérationnelle
| Director/Board Member | 7 |
| Founder | 4 |
| Independent Dir/Board Member | 3 |
Sectorielle
| Health Technology | 11 |
| Consumer Services | 3 |
| Consumer Non-Durables | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 6 |
|---|---|
| LADRX CORPORATION | Health Technology |
| REGENICIN, INC. | Health Technology |
| COLGATE-PALMOLIVE COMPANY | Consumer Non-Durables |
| AMGEN INC. | Health Technology |
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| AMARANTUS BIOSCIENCE HOLDINGS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
| Cetus Corp. | Health Technology |
Schering-Plough Corp.
 Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
SuperGen, Inc.
SuperGen, Inc. Pharmaceuticals: MajorHealth Technology SuperGen, Inc. researches and develops drugs, diagnostics and other therapeutic products. It discovers and develops novel cancer therapies and drugs. SuperGen buys rights to drugs in advanced stages of development and bring them to market. The company's major product is Nipent it is used for graft-versus-host disease, which afflicts bone marrow transplant recipients and various forms of lymphoma. SuperGen also makes a few generic cancer drugs like paclitaxel. The company was founded on March 6, 1991 by David M Fineman and Elliott L. Fineman and is headquartered in Dublin, CA. | Health Technology |
Imcure Therapeutics, Inc.
Imcure Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Imcure Therapeutics, Inc. provides biopharmaceutical products. The firm develops small molecule therapeutics to treat diseases. The company was founded by Joseph Rubinfeld in December 2003 and is headquartered in San Francisco, CA. | Health Technology |
Vivacitas Oncology, Inc.
Vivacitas Oncology, Inc. Medical/Nursing ServicesHealth Services Vivacitas Oncology, Inc. is a private clinical stage biopharmaceutical company founded in 2015 by Dr. Joseph Rubinfeld and Infusion 51a, LP. The company is based in Walnut Creek, CA. Vivacitas Oncology is focused on combating cancers that have proven to be resistant to current treatment modalities. The company aims to improve upon well-known chemotherapies with demonstrated effect, but which also possess challenges with potency, toxicity, stability, and other issues limiting their use. The CEO is Mark J. Suseck. | Health Services |
- Bourse
- Insiders
- Joseph Rubinfeld
- Expérience
